AbCellera Biologics (NASDAQ: ABCL) revenue
AbCellera Biologics reported revenue of $75.1m for fiscal 2025, 160.6% more than in fiscal 2024 ($28.8m). Since fiscal 2020 its revenue has fallen by 67.8%, an average decline of 20.3% a year.
AbCellera Biologics's best year of the last 6 was fiscal 2022. The biggest drop was in fiscal 2023, −92.2%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $75.1m | +160.6% | −$217.1m | −289.0% |
| 2024 | $28.8m | −24.2% | −$314.8m | −1,091.7% |
| 2023 | $38.0m | −92.2% | −$237.2m | −623.8% |
| 2022 | $485.4m | +29.4% | $216.5m | 44.6% |
| 2021 | $375.2m | +60.9% | $204.4m | 54.5% |
| 2020 | $233.2m | — | $156.0m | 66.9% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
AbCellera Biologics revenue compared with its sector
By revenue for its latest fiscal year, AbCellera Biologics ranks 307th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; AbCellera Biologics, 160.6%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 305th | Sight Sciences | $77.4m | −3.1% |
| 306th | CytomX Therapeutics | $76.2m | −44.8% |
| 307th | AbCellera Biologics | $75.1m | 160.6% |
| 308th | Recursion Pharmaceuticals | $74.7m | 26.9% |
| 309th | Electromed | $73.8m | 15.3% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of AbCellera Biologics
- How much revenue did AbCellera Biologics make in fiscal 2025?
- AbCellera Biologics reported revenue of $75.1m for fiscal 2025, compared with $28.8m in fiscal 2024.
- How much has the revenue of AbCellera Biologics fallen?
- Between fiscal 2020 and fiscal 2025 it went from $233.2m to $75.1m: 67.8% less, an average decline of 20.3% a year.
- What was the best year for revenue at AbCellera Biologics?
- Of its last 6 fiscal years, fiscal 2022, with $485.4m.
- Where does AbCellera Biologics rank in its sector by revenue?
- It ranks 307th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for AbCellera Biologics come from?
- From the annual report (Form 10-K) that AbCellera Biologics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that AbCellera Biologics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on AbCellera Biologics: the AbCellera Biologics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.